Core Insights - Profound Medical Corp. has announced the successful completion of its 100th TULSA Procedure™ at Dallas Medical Center, marking a significant milestone in the adoption of its innovative prostate treatment technology [1][2] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing AI-powered, MRI-guided, incision-free therapies for treating diseased tissue, particularly in prostate care [1][3] - The company's flagship product, the TULSA-PRO system, allows for precise, real-time MRI-guided prostate therapy, enhancing treatment personalization and minimizing side effects associated with traditional surgical methods [4][6] Technology and Innovation - The TULSA Procedure utilizes robotically controlled directional ultrasound to heat prostate tissue to 'kill temperature' (55-57°C), while protecting surrounding anatomy, resulting in no procedural blood loss and quicker recovery times [2][4] - Real-time MRI thermography enables continuous visualization and autonomous temperature adjustments during the procedure, allowing for tailored therapy for each patient [2][4] Market Adoption and Growth - Following a transition to a Medicare model, the TULSA Procedure's adoption increased by 500%, indicating strong market demand and interest from urologists across Texas and surrounding states [2] - The innovative model developed by Texas Prostate bridges private-pay practices and Medicare-participating hospitals, facilitating broader access to advanced prostate care [2] Additional Products - Profound Medical also markets Sonalleve, an MRI-guided therapy for non-surgical treatment of various conditions, including pain palliation for bone metastases and gynecologic issues, which also emphasizes incision-free treatment and faster recovery [5][7] Regulatory Approvals - Profound Medical's technologies, including TULSA-PRO and Sonalleve, are approved in major global markets, including the United States, Europe, Canada, and several other countries, expanding access to innovative treatment options [6][7]

Core Insights - Profound Medical Corp. announced the superiority of the TULSA Procedure over robotic radical prostatectomy (RP) in terms of primary safety endpoints in the CAPTAIN trial for men with intermediate-risk prostate cancer [1][5] Group 1: CAPTAIN Trial Overview - The CAPTAIN trial exceeded its enrollment target, treating 211 patients across 20 sites in the U.S., two in Canada, and one in Europe by August 2025 [2] - The trial aimed to compare the safety and efficacy of the TULSA Procedure with RP, focusing on preserving erectile function and urinary continence [8] Group 2: Clinical Outcomes - At 6 months post-treatment, 50% of patients preserved both erectile function and urinary continence after TULSA compared to 24% after RP, indicating a statistically significant improvement (p<0.05, risk ratio 2.1) [5] - TULSA preserved pad-free continence in 84% of men, while only 49% achieved this after RP [5] - Patient-reported erectile function was preserved in 56% of TULSA patients compared to 47% after RP [5] Group 3: Perioperative Measures - TULSA demonstrated zero blood loss during the procedure, while RP had an average blood loss of 150 mL (p<0.001) [5] - Patients undergoing TULSA had a shorter recovery time, missing an average of 10 days from work compared to 19 days for RP (p<0.05) [5] - There were significantly fewer serious complications requiring hospitalization after TULSA (0.7%) compared to RP (6.3%) within 90 days (p<0.05) [5] Group 4: Future Implications - The CAPTAIN trial is positioned to potentially establish the TULSA Procedure as a standard of care for prostate cancer treatment, with secondary oncologic outcomes expected later this year [6][8] - The trial's design allows for a rigorous comparison of safety, quality of life, and oncological control between the two treatment modalities [6]

Core Insights - The CAPTAIN trial demonstrates that the TULSA Procedure shows significant improvement over robotic radical prostatectomy (RP) in preserving erectile function and urinary continence at 6 months post-treatment [1][3][5] Group 1: Trial Overview - CAPTAIN trial successfully exceeded its enrollment target, treating 211 patients across 20 sites in the U.S., two in Canada, and one in Europe by August 2025 [2] - The trial aims to compare the safety and efficacy of the TULSA Procedure with RP in men with localized, intermediate-risk prostate cancer [7] Group 2: Clinical Outcomes - At 6 months, 50% of patients preserved both erectile function and urinary continence after TULSA compared to 24% after RP, with a statistically significant p-value of <0.05 [3] - TULSA preserved pad-free continence in 84% of men, while only 49% achieved this after RP [3] - Patient-reported erectile function was preserved in 56% of TULSA patients compared to 47% after RP [3] Group 3: Perioperative Measures - TULSA showed zero blood loss compared to 150 mL after RP, with a significant p-value of <0.001 [3] - Patients undergoing TULSA had a shorter recovery time, missing an average of 10 days from work compared to 19 days for RP [3] Group 4: Complications and Safety - The rate of serious complications within 90 days was significantly lower for TULSA at 0.7% compared to 6.3% for RP [3] - No patients required ICU admission after TULSA, while 1.6% did after RP [3] Group 5: Future Outlook - Secondary oncologic outcomes from the TULSA Procedure are expected to be reported later this year, which will provide further insights into its efficacy [4][5] - The trial positions the TULSA Procedure as a potential standard of care in prostate cancer treatment, pending further results [5][6]

Core Insights - Profound Medical Corp. announced that Dr. Pejman Ghanouni received the Cum Laude award for his presentation on the CAPTAIN trial comparing MRI-guided TULSA Procedure with robotic radical prostatectomy at the RSNA Annual Meeting 2025, highlighting the significance of this recognition in the medical community [1][2][3] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [5][6] - The company is commercializing the TULSA-PRO system, which utilizes real-time MRI and AI-enhanced planning for precise prostate tissue ablation, aiming to become a mainstream treatment for various prostate conditions [6][7] TULSA Procedure Details - The TULSA Procedure is a non-invasive treatment that uses robotically controlled ultrasound to ablate prostate tissue while preserving surrounding structures, offering advantages such as no blood loss, no overnight hospital stay, and quicker recovery times compared to traditional surgical methods [3][7] - The procedure is designed to be performed in a single session, taking a few hours, and is suitable for a wide range of prostate shapes and sizes [7] CAPTAIN Trial Insights - The CAPTAIN trial is a multi-center randomized controlled study comparing the safety and efficacy of the TULSA Procedure with robotic radical prostatectomy in men with organ-confined, intermediate-risk prostate cancer, with 210 patients randomized as of January 2025 [4] - The trial's results indicate that patients undergoing the TULSA Procedure experience significantly shorter recovery times, with many feeling back to normal the day after the procedure, compared to an average of three weeks for robotic surgery patients [3][4] Recognition and Awards - Dr. Ghanouni's presentation was one of only six to receive the Cum Laude award at RSNA 2025, representing the top 5% of scientific posters, underscoring the quality and impact of the research presented [2][3] - Additionally, Dr. Satoru Takahashi received a Certificate of Merit for his work on TULSA, further validating the procedure's emerging role in prostate cancer treatment [3]